Accessibility Menu
Oaktree Acquisition Corp. III Life Sciences logo

Oaktree Acquisition Corp. III Life Sciences(NASDAQ) OACC

Market Cap$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)+7%
5 YearN/A
1 Year+3%
1 Month+0%
$10.79
+0.65%
+0.07Today
Oaktree Acquisition Corp. III Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 10.742026-08-04
Oaktree Acquisition Corp. III Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 10.742026-07-28
1 month+0%USD 10.742026-07-02
3 month+1.23%USD 10.612026-05-06
Year to date+1.51%USD 10.582025-12-31
1 year+2.58%USD 10.472025-08-04
Since inception+7.4%USD 10.002024-12-16

Oaktree Acquisition Corp. III Life Sciences Financials at a Glance

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$7.02M

EPS (TTM)

$0.29

P/E Ratio

37.59

Dividend

$0.00

Beta (Volatility)

0.12 (Low)

Price

$10.79

Volume

6

Open

$10.75

Previous Close

$10.74

Daily Range

$10.74 - $10.77

52-Week Range

$10.30 - $10.88

Estimated Earnings Date

Oct 1, 2025

OACC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition helps life science companies go public. It looks for promising businesses in healthcare and medicine. The goal is to merge with a private company.

Finding a Healthcare Partner

  • Target Identification: Finding private businesses in the biopharmaceutical, medical device, and diagnostics sectors; focuses on North America and Europe.
  • Merger Services: Managing the legal and financial steps to turn a private firm into a public one.
  • Capital Funding: Providing cash from a trust account to support a new partner's future growth.

The Growth Roadmap

  • Raised $175 million through its initial public offering on October 25, 2024.
  • Increased total funds by roughly $17 million through an over-allotment option on October 30, 2024.
  • Secured funding for search costs from Oaktree Acquisition Holdings III LS, LLC in late 2024.

What Makes it Different?

The company focuses exclusively on the life sciences sector in North America and Europe. It uses deep financial expertise from Oaktree Capital Management to evaluate complex medical technology businesses.

The Financial Scorecard

  • Net income reached $1.4 million in Q1 2026, down 16% from $1.7 million in Q1 2025.
  • Operating loss was $456,538 in Q1 2026, a 2.6% worsening compared to the previous year.
  • Cash held in the trust account grew to $203.4 million as of March 31, 2026.
  • Market capitalization dropped to $203.1 million in Q1 2026, down 19.2% from $251.5 million in Q1 2025.

Bottom Line

Oaktree Acquisition is a shell company currently searching for its first business merger. Its progress depends on successfully acquiring a life sciences firm before its October 2026 deadline.

AI Generated • May 16, 2026

Industry

Banks

Sector

Financials

Employees

3

CEO

Zaid Pardesi, MBA

Website

www.oaktreeacquisitioncorp.com/oac-iii

Headquarters

Los Angeles, CA 90071, US

OACC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

3.63%

Return on Capital

-0.61%

Return on Assets

3.43%

Earnings Yield

2.66%

Dividend Yield

0.00%

Payout Ratio

1.21%

Stock Overview

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.58M

Volume

6

Avg. Volume

19.75K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.21M

EBITDA

-$1.21M

Operating Cash Flow

-$490.43K

Capital Expenditure

$3.00

Free Cash Flow

-$490.42K

Cash & ST Invst.

$1.28M

Total Debt

$11.82K

Oaktree Acquisition Corp. III Life Sciences Performance Analysis

Oaktree Acquisition Corp. III Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Oaktree Acquisition Corp. III Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD 0.05N/A
20252025-12-31USD 0.30447.0%
Oaktree Acquisition Corp. III Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.9%
Q32025-09-305.0%
Q42025-12-31-9.0%
Q12026-03-31-17.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$264.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$88.01M

N/A

Employees

3

N/A

Net Income

$1.39M

-16.0%

EBITDA

-$456.54K

-127.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.28M

-0.4%

Total Debt

$11.82K

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$11.82K

+0.0%

Return on Assets

3.43%

N/A

Return on Invested Capital

-0.59%

N/A

Free Cash Flow

-$158.04K

-76.2%

Operating Cash Flow

-$158.04K

-76.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOULSoulpower Acquisition Corp.
$10.40+0.00%
FACTFACT II Acquisition Corp
$10.65-0.08%
PMTRPerimeter Acquisition Corp. I Class A Ordinary Shares
$10.39-0.18%
COPLCopley Acquisition Corp
$10.50+0.19%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$116.12-0.07%
NVDANvidia
$221.18+0.04%
INLFInlif
$6.56+1.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.20-0.01%

Questions About OACC

What is the current price of Oaktree Acquisition Corp. III Life Sciences?

Oaktree Acquisition Corp. III Life Sciences is trading at $10.74 per share.

What is the 52-week range for Oaktree Acquisition Corp. III Life Sciences?

Over the past 52 weeks, Oaktree Acquisition Corp. III Life Sciences has traded between $10.30 and $10.88.

How much debt does Oaktree Acquisition Corp. III Life Sciences have?

As of the most recent reporting period, Oaktree Acquisition Corp. III Life Sciences reported total debt of $11.82K.

How much cash does Oaktree Acquisition Corp. III Life Sciences have on hand?

Oaktree Acquisition Corp. III Life Sciences reported $1.28M in cash and cash equivalents in its most recent financial results.

What is Oaktree Acquisition Corp. III Life Sciences’s dividend yield?

Oaktree Acquisition Corp. III Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services